Research managers jan 14th, 2016 - ipposi presentationipposi
Irish Platform for Patient Organisations, Science & Industry - the importance of patient involvement in research, and patient training on medicines development and health research.
Tell me and I forget, teach me and I remember, involve me and I learnSimon R. Stones
This presentation was delivered at the Glasgow Caledonian University School of Health and Life Sciences Research Seminar, to help inform the group who are currently developing their strategy for patient and public involvement and engagement.
Research managers jan 14th, 2016 - ipposi presentationipposi
Irish Platform for Patient Organisations, Science & Industry - the importance of patient involvement in research, and patient training on medicines development and health research.
Tell me and I forget, teach me and I remember, involve me and I learnSimon R. Stones
This presentation was delivered at the Glasgow Caledonian University School of Health and Life Sciences Research Seminar, to help inform the group who are currently developing their strategy for patient and public involvement and engagement.
On 14 November 2019, our Research and Advocacy Manager, Laura Kavanagh delivered this presentation on ‘the Drug Iceberg report’ to participants at the Retina Roundtable. The Roundtable kicked off a three-day conference around the topic of ‘Evidence Generation for Access to Innovative Therapies’. IPPOSI was asked to outline the access to medicine challenges faced by patients in Ireland, including the health technology assessment (HTA) and post-HTA processes.
A presentation delivered by IPPOSI CEO, Derick Mitchell at the University College Dublin PharmTox Society event on Clinical Trials in Ireland on March 6th, 2017
A presentation delivered by IPPOSI CEO, Derick Mitchell at the Irish Brain Council-Neurological Allinace of ireland joint event in the Science Gallery, Dublin on March 7th, 2017.
A presentation delivered by IPPOSI CEO, Derick Mitchell at a conference organised by the Clinical Research Facility, St. James's Hospital, Dublin, May 2018
EUPATI Status Update at EMA PCWP Meeting, 26 Nov 2015jangeissler
Overview and Status Quo of the European Patients Academy (EUPATI) project, presented by EUPATI Director Jan Geissler at the EMA Patient and Consumer Working Party (PCWP) meeting in London on 26 Nov 2015
Through our longstanding support of the University of Ontario Institute of Technology (UOIT), Purdue Pharma (Canada) continues to encourage innovation, discovery and scientific exploration.
NeuroRescescue EU Cluster of Excellence on NeurosciencePARC DE SALUT
PARC DE SALUT is the Catalan Cluster member of NeuroRescue, the Cluster of Excellence on Neurosciences, supported by the EC’s Regions of Knowledge Program. More information on: www,neurorescue.eu and www.parcdesalut.com/neurorescue
On 14 November 2019, our Research and Advocacy Manager, Laura Kavanagh delivered this presentation on ‘the Drug Iceberg report’ to participants at the Retina Roundtable. The Roundtable kicked off a three-day conference around the topic of ‘Evidence Generation for Access to Innovative Therapies’. IPPOSI was asked to outline the access to medicine challenges faced by patients in Ireland, including the health technology assessment (HTA) and post-HTA processes.
A presentation delivered by IPPOSI CEO, Derick Mitchell at the University College Dublin PharmTox Society event on Clinical Trials in Ireland on March 6th, 2017
A presentation delivered by IPPOSI CEO, Derick Mitchell at the Irish Brain Council-Neurological Allinace of ireland joint event in the Science Gallery, Dublin on March 7th, 2017.
A presentation delivered by IPPOSI CEO, Derick Mitchell at a conference organised by the Clinical Research Facility, St. James's Hospital, Dublin, May 2018
EUPATI Status Update at EMA PCWP Meeting, 26 Nov 2015jangeissler
Overview and Status Quo of the European Patients Academy (EUPATI) project, presented by EUPATI Director Jan Geissler at the EMA Patient and Consumer Working Party (PCWP) meeting in London on 26 Nov 2015
Through our longstanding support of the University of Ontario Institute of Technology (UOIT), Purdue Pharma (Canada) continues to encourage innovation, discovery and scientific exploration.
NeuroRescescue EU Cluster of Excellence on NeurosciencePARC DE SALUT
PARC DE SALUT is the Catalan Cluster member of NeuroRescue, the Cluster of Excellence on Neurosciences, supported by the EC’s Regions of Knowledge Program. More information on: www,neurorescue.eu and www.parcdesalut.com/neurorescue
Tesztgenerálás a gyakorlatban - Az IntelliTest és ami mögötte vanDávid Honfi
Egységtesztek manuális származtatása legtöbb esetben specifikáció alapján történik, ám magas kódfedettség a tesztesetek automatikus generálásával is elérhető. A forráskód alapján történő generáláshoz számos technika és eszköz áll rendelkezésre, amelyek hasznos kiegészítői lehetnek a fejlesztői és tesztelői eszköztárnak. Az előadás bemutatja a forráskód alapú tesztbemenet-generáló módszereket, és egy konkrét .NET-es egységteszt-generáló megoldás, a Microsoft IntelliTest eszközével kapcsolatos tapasztalatokat.
EUPATI’s framework on Informing the “health-interested” public about medicine...Nowgen
"EUPATI's framework on Informing the “health-interested” public objectively and comprehensively about medicines R&D", presented by Jan Geissler at the EUPATI 2014 Workshop in Warsaw
EU Clinical Trials Regulation - IPPOSI perspectiveipposi
IPPOSI CEO, Dr Derick Mitchell delivered a presentation on the EU Clinical Trials Regulation from the patients' perspective at the 20th International Conference on Pharmaceutical Medicine, Athens, Greece.
UCD Rare Disease Module 2017 - Dr Derick Mitchell - March 28th 2017ipposi
Medical students taking the elective course in rare diseases are provided a number of patient perspectives throughout the module. This is what IPPOSI presented in 2017.
Education of patients (advocates) on R&D: European Patients’ Academy EUPATI...jangeissler
"Education of patients (advocates) on R&D: European Patients’ Academy EUPATI", presented by Jan Geissler at the Careum Congress on 18 March 2014 in Basel
European Patients’ Academy on Therapeutic Innovation:Shifting paradigms in ...patvocates
"European Patients’ Academy on Therapeutic Innovation: Shifting paradigms in empowering patients on medical R&D": Presentation by Jan Geissler (Twitter @jangeissler) at the Belgian Association of Clinical Research Professionals (ACRP.be) meeting on 25 Oct 2012
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...EUPATI
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 June 2013, presented by Jan Geissler (@jangeissler), Director EUPATI (@EUPATIents) at the IMI's "Patient Focus" meeting, convening patient leaders from across Europe
Patient Advocates in Cancer Research: European Patients’ Perspective - Jan ...patvocates
Patient Advocates in Cancer Research: European Patients’ Perspective, presented by Jan Geissler (Twitter @jangeissler) at ISOQOL 19th Annual Conference, Budapast, 26 Oct 2012
ISPOR Eupati meeting - Dr Derick Mitchell - November 2017ipposi
The IPPOSI CEO delivered a presentation at the international HTA conference about IPPOSI's role in EUPATI and the importance of engaging patients in HTA and health innovation R&D.
Let's talk people in research sept 2014Simon Denegri
This slide-deck covers the main components of current NIHR approaches towards public involvement in research; its ongoing strategic review of the area and; its current policy towards engaging patients through the NHS.
EUPATI 2013 Conference: Patient involvement in medicines R&D: Bringing to li...EUPATI
"Patient involvement in medicines R&D: Bringing to life with EUPATI", presented by Jan Geissler, EUPATI Director, at the EUPATI 2013 Conference on 19 April 2013
Derick Mitchell_Biobanking from the patient perspective.pdfipposi
IPPOSI CEO Derick Mitchell presented the patient perspective on biobanking at the 2023 WECAN Academy for Cancer Patient Advocates on July 2nd, 2023 in Frankfurt, Germany.
Mental Health - Leading the data sharing charge with a rights-based approachipposi
Frankie Prendergast's (Digital Health Applications Programme Manager in St Patrick's Mental Health Services) presentation on health information at the 2023 IPPOSI Conference.
Muiris O'Connor, Assistant Secretary of the Department of Health, presented key government updates on health information at the 2023 IPPOSI Conference Building a Data Sharing Health Sector in Ireland.
Clinical Workflow for Capture of Patient Registry Dataipposi
Clare Harney, Managing Director of HD Health, gave a lightning presentation on managing data for patient registries at the 2023 IPPOSI Conference on Building a Data Sharing Health Sector in Ireland.
Patient Centricity in Value-based healthcare, Sept 2022ipposi
IPPOSI CEO Derick Mitchell delivered a presentation as part of the RCSI Value Based Healthcare Webinar on Patient Centricity on Sept 18th, 2022.
The Future of Value Based Healthcare in Ireland webinar series is run by The RCSI Healthcare Outcomes Research Centre, Janssen Sciences Ireland UC and Novartis Ireland.
2022 World Day Brain Event - IPPOSI Presentationipposi
Laura Kavanagh, Research and Advocacy Manager in IPPOSI, gave a presentation on World Brain Day 2022 at an event hosted by the Neurological Alliance of Ireland.
In October 2020, IPPOSI published a membership engagement survey on its draft 4-year strategy. This slide deck captures the summary results of the survey.
IPPOSI CEO Derick Mitchell delivered a presentation on Dec 6th 2019 at the Digital health Conference, organised as part of the Royal College of Physicians, Ireland
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
2. My presentation today
• IPPOSI?
• Patient involvement in Research
• Clinical Research / Clinical Trials
• Patient Training
• European Patients Academy (EUPATI)
3. IPPOSI? Who?IPPOSI
Mission
We expedite development of and patient access to innovative therapies through a
unique partnership of Patient Groups, Industry and Science
Priorities
• Bring a patient perspective to clinical research in Ireland
• Actively influence policy that impacts on research and access to innovative therapies
“Putting patients in policy and medicines development”
8. IPPOSI Funding
• Grant from Department of Health
(via Health Research Board)
• Industry membership fee
9. Patient involvement in research
Distinct from:
• Raising awareness
• Sharing knowledge
• Creating a dialogue with the public
• Recruitment of people as participants in research
Active partnership between members of the public and
researchers in the research process
11. Patient involvement in research can:
• Provide a different perspective
• Make language + content of information clear and accessible
• Help to ensure study methods are acceptable and sensitive
• Help ensure that research uses outcomes that are important to the public
• Help increase participation in research
13. Clinical Trial Activity in Ireland?
*Including only open studies, excluding studies with unknown status
Data Source: Clinicaltrials.Gov
13
14. What do Irish people think?
26 12 20 12 29 1
50 15 16 5 14
56 14 11 4 14 1
60 17 14 3 5 2
I would only participate in
clinical trials if I was very
sick
I would be willing to supply
personal medical
information for medical
research if it is done in a
confidential manner
I would be willing to donate
blood to be used for clinical
research
I think carrying out clinical
research in Ireland with the
aim of developing new ways
to treat many diseases is a
good idea
Strongly agree Agree Neither/nor Disagree Disagree strongly DK
{Base: n=1000, All adults}
Irish general public’s attitude
towards clinical research,
Nov. 2009
15. Conclusion
• Limited understanding of how one can participate
• (i.e. donating blood/tissue, medical information)
• Ethical concerns
• Unnecessary Risk
17. Training Patients
• IPPOSI Annual Training
• December 9th, 2015
9:00-12:00pm
Boston College,
St. Stephen’s Green,
Dublin 2
18. Where can we go from here?
More Public Information More Patient & Researcher Training Improve Research Environment
19. Patients as partners of research:
More needs to be done!
“Rare cancers will never be a priority unless the patients
make it one. Patients themselves must therefore play a
larger role in driving forward the search for therapies.”
Amy Dockser Marcus (@AmyDMarcus)
20. Good Shepherds
“Involving patients in all your research from design
to implementation increases your chances of
success”
Graham Love, CEO Health Research Board
“We need to engage clinicians and patients from the
start, understand what their priorities are, and explain
what the benefits can be, instead of being overly
bureaucratic.”
Richard Corbridge, Chief Information Officer, HSE
22. • Patient‘s organisations have unique insights in “real life“ and
“real needs“ of patients:
• Clinical trial design
• Priority setting
• Research policy
• Training required to get the expertise required to contribute to
research & development projects
Building a new environment for research
22
23. IPPOSI & EUPATI
• EUPATI produces Expert Patients on Medicines Research
& Development
• Provides Training & Education
• Disseminates through national platforms
The project is receiving support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115334, resources of which are composed of financial
contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies.
24. EUPATI Patient Experts
Training Course
EUPATI develops patient education
targeted towards different audiences
53+50
patient
experts
EUPATI Educational
Toolbox
EUPATI
Internet Library
English
French
German
Spanish
Polish
Italian
Russian
English
Patient
advocates
(12,000)
Health-
interested
public
(100,000)
25. Three years of EUPATI:Much has been done! …
Reflection, consensus, dialogue, community building,
Engagement at EUPATI workshops in Frankfurt, Barcelona, Rome, Warsaw, Dublin
103 Patient Expert Trainees
Online Toolbox available in January 2016
26. Areas covered by the Patients’ Academy
1.Medicines development process from research to approval
2. Personalized and predictive medicine
3.Drug safety and risk/benefit assessment of medicines
4. Pharmaco-economics, health economics and health technology assessment
5. Design and objectives of clinical trials
(& roles of stakeholders)
6. Patients roles & responsibilities in medicines
development
…and NOT:
develop indication-
or therapy-specific
information!
27. Irish National Platform
• Rachel Lynch, FibroIreland
• Damien Peelo, COPD Support Ireland
• Julie Power, Vasculitis Ireland Awareness
• Sharon Thompson, Rare Dis. + Palliative care
• John Dowling, Men Against Cancer
• Caitriona Dunne, Fighting Blindness
• Joan Jordan, MS Ireland
• Katie Murphy, CF Ireland
8 Irish Trainees
29. Take Home Messages
Patient involvement in research is here to stay
Education + Training of both patients & researchers are
key principles
@IPPOSI www.ipposi.ie